Investors / United States / Ono Venture Investment
Ono Venture Investment
Corporate VC · Cambridge, MA, United States · North America
Ono Venture Investment is the corporate venture capital arm of Ono Pharma, an R&D-oriented pharmaceutical company. It invests in early-stage startup companies with technologies, drug targets, products and platforms that could have high synergy with Ono Pharma's R&D.
Invests inHealthcare & Biotech
In its own wordsoncologyimmunologyinflammationneurologypharmaceuticalscorporate venture capital
Your fit with Ono Venture Investment
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsOno Venture Investment lists 14 checked portfolio companies on its own site and is named in 3 funding rounds, 1 of them as lead. Its most frequent entry is Series A, 67% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 60% of its companies are based in United States. It invests most often alongside ARCH Venture Partners, Agent Capital and LifeLink Ventures.
Counts come from funding rounds that name Ono Venture Investment, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Ono Venture Investment's whole history. Rounds on record name 3 companies; its own site lists 14. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 33% |
| Series A | 67% |
| Series B | 0% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 1 |
| '26 | 2 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 33th | 13 companies |
| Recent activity | 69th | 2 rounds in 12 months |
| Early stage | 64th | 33% of entries at pre-seed or seed |
| Evidence | 94th | 23% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 78th | 5 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| ARCH Venture Partners | 3 |
| Agent Capital | 2 |
| LifeLink Ventures | 2 |
| Sofinnova Partners | 2 |
| +ND Capital | 1 |
| 120 Capital | 1 |
| Altitude Life Science Ventures | 1 |
| Amplitude Ventures | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers14100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with ARCH Venture Partners
Compare Ono Venture Investment head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Ono Venture Investment| Date | Company | Stage |
|---|---|---|
| 24 Sept 2026 | Series A | |
| 13 May 2026 | Seed | |
| 9 Sept 2025 | Series A Led |
Round details for Ono Venture Investment
Amounts, full round histories and every co-investor in Ono Venture Investment's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
14 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Airna is developing novel medicines with the potential to deliver functional cures for patients using RNA editing technology. | Healthcare & Biotech | Portfolio page | ||
| Alchemab Therapeutics develops antibody therapeutics for hard to treat diseases using the immune system | Healthcare & Biotech | Sept 2025Series A | Page + round | |
| Arbor Biotechnologies develops novel gene editing treatments for people living with genetic disease | Healthcare & Biotech | Portfolio page | ||
| Casma Therapeutics is developing novel cellular degradation approaches based on the autophagy pathway to initiate new target areas for drug discovery and development | Healthcare & Biotech | Portfolio page | ||
| Harness Therapeutics develops disease-modifying therapies for neurodegenerative diseases | Healthcare & Biotech | Portfolio page | ||
| Immunitas Therapeutics discovers and develops novel therapeutics for patients with cancer and autoimmune diseases. | Healthcare & Biotech | Portfolio page | ||
| Mediar Therapeutics is developing treatments for fibrotic diseases by targeting the myofibroblast cell | Healthcare & Biotech | Portfolio page | ||
| The company provides early-stage capital to life science entrepreneurs and offers shared lab space to support their development, from idea to exit. | Healthcare & Biotech | Portfolio page | ||
| Monimoi Therapeutics is delivering transformative therapies by harnessing the potential of covalent medicines and chemical proteomics for cancer treatment. | Healthcare & Biotech | Portfolio page | ||
| Mozart Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapies that effectively treat and potentially cure autoimmune disease. | Healthcare & Biotech | Portfolio page | ||
| Photys Therapeutics is a proximity-based therapeutics company advancing a new generation of targeted protein modulation medicines. | Healthcare & Biotech | Portfolio page | ||
| Switch Therapeutics is developing biomarker-gated, innovative genetic medicines to transform the treatment of central nervous system diseases. | Healthcare & Biotech | Portfolio page | ||
| United Immunity develops next-generation in vivo cell therapies using its Myeloid Targeting Platform technology to selectively target and program immune cells in the body for the treatment of various diseases. | Healthcare & Biotech | Sept 2026Series A | Page + round | |
| Violet Therapeutics is a therapeutics company leveraging a proprietary platform for the identification of cell-to-cell interactions with a focus on diseases of the central nervous system. | Healthcare & Biotech | May 2026Seed | Page + round |
About this data
site last read 5 Nov 2026- Site
- onoventure.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 9 Sept 2025
- Companies checked
- 14
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Ono Venture Investment's profile as data
Pull Ono Venture Investment's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/onoventure.com
# also
GET /v1/firms/onoventure.com/portfolio
GET /v1/firms/onoventure.com/coinvestors
GET /v1/firms/onoventure.com/news